Watch our Webinar: The power of nutrition and mitochondrial diseases
Watch our Webinar: The power of nutrition and mitochondrial diseases As part of LHON Awareness Day, we hosted a powerful […]
Homepage News
From Advocacy to Access: Mito Community Celebrates FDA Milestone
Barth syndrome therapy sets precedent for future treatments targeting mitochondrial dysfunction In a landmark decision, the U.S. Food and Drug
IMP Launches New TK2d Video
IMP Launches New TK2d Video To mark TK2d Awareness Day 2025, we’ve released a new video that amplifyies the voices
IMP Welcomes Three New Members
IMP now has members across three continents We’re delighted to welcome three new members to IMP. With these new members,
Landmark Success for Mitochondrial Donation: A Milestone for Families Worldwide
The birth of eight healthy babies in the UK through mitochondrial donation (also known as Mitochondrial Replacement Therapy) has been
IMP Announces New Board Following Election
IMP is delighted to announce the results of its recent Board elections, confirming a dynamic and diverse leadership team that
Scientists provide first evidence that the drug sildenafil may benefit patients with Leigh syndrome, and particularly those carrying mutations in the mitochondrial gene MT-ATP6.
The PolG Foundation: Advancing Research and Hope for POLG Disorders
The PolG Foundation is committed to accelerating research efforts to develop effective treatments and, ultimately, a cure for POLG mitochondrial disorders.
LHON Awareness Day Webinar
During this year’s World Mitochondrial Disease Week, IMP hosted a free webinar on 19 September for LHON Awareness Day. The theme for the webinar was LHON and Gene Therapy: Where are they now?
Khondrion announces publication of results of integrated Phase 2b programme
On 7 November, biopharmaceutical company Khondrion announced the publication of results from their integrated Phase 2b clinical development programme which uses the drug sonlicromanol to target the underlying pathways of primary mitochondrial disease.